At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,778 enrolled
Drug / intervention
Pirfenidone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of the Dose Reduction and Discontinuation Associated With Anti-Fibrotic Medications in Patients With Idiopathic Pulmonary Fibrosis
In Brief
An observational study evaluating Pirfenidone and Nintedanib for Idiopathic Pulmonary Fibrosis. Completed, enrolled 2,778 participants across 1 site.
Detailed Summary
The overarching aim of our study is to assess the incidence of dose reduction and discontinuations for pirfenidone and nintedanib.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
202420252026
First PostedMar 2023
Enrollment StartApr 2023
Primary CompletionJul 2023
TodayJul 2026
First PostedMar 22, 2023
Enrollment StartApr 18, 2023
Primary CompletionJul 14, 2023
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 3.3 years ago
Interventions
Pirfenidonedrug
Pirfenidone
Nintedanibdrug
Nintedanib